32 results about "Proton-pump inhibitor" patented technology

Veterinary pharmaceutical compositions for direct systemic introduction, also known as DSI pharmaceutical compositions. One veterinary pharmaceutical composition for direct systemic introduction includes about 10-17 dry mass % bovine gelatin; about 10-17 dry mass % mannitol; about 0-1 dry mass % of a surfactant; and about 65-80 dry mass % of the active pharmaceutical ingredient which is a proton pump inhibitor. A method of manufacturing a veterinary pharmaceutical composition for direct systemic introduction includes combining one or more pharmacologically inactive compounds to form a first solution; using one or more surfactants to form a second solution; adding an active pharmaceutical ingredient to the second solution to form a first mixture; adding the first solution to the first mixture to form a pre-formulation; freezing the pre-formulation; and lyophilizing the pre-formulation.

The present disclosure relates to storage-stable proton pump inhibitor (PPI) systems comprising a therapeutically effective amount of a PPI or a pharmaceutically acceptable salt thereof, such as omeprazole or a pharmaceutically acceptable salt thereof, which are constituted with water prior to administration. The present disclosure also relates to oral pharmaceutical suspensions comprising water, a therapeutically effective amount of a PPI or a pharmaceutically acceptable salt thereof, such as omeprazole or a pharmaceutically acceptable salt thereof, and one or more buffering agents.

The invention provides a primer combination for detecting helicobacter pylori and application of the primer combination. The primer combination is used for strain identification of the helicobacter pylori and detection of gastric cancer risk sites, antibiotic resistance sites, virulence genotyping and human proton pump inhibitor drug metabolism. On the basis of multiple PCR and targeted high-throughput sequencing technologies, specific targeted amplification primers are designed and mixed, so that the helicobacter pylori identification can be completed, gastric cancer risk sites, antibiotic resistance genes, virulence typing and human proton pump inhibitor drug metabolism genes of the helicobacter pylori can be detected, and finally, the helicobacter pylori can be detected. A quantitative algorithm of approximate concentration of helicobacter pylori is also introduced into the system, so that more sensitive, accurate and comprehensive detection of helicobacter pylori is realized.

The invention belongs to the technical field of proton pump inhibition medicine preparations, and relates to a rabeprazole sodium enteric-coated tablet and a preparation method thereof. The technical problems that an existing rabeprazole sodium enteric-coated tablet is insufficient in stability, lagged in dissolution and the like are solved. The enteric-coated tablet consists of a tablet core and an enteric-coated coating layer wrapped outside the tablet core, wherein the tablet core comprises auxiliary materials such as rabeprazole sodium, a filling agent, an adhesive, a stable dissolution promoter and the like; the enteric coating layer comprises an enteric coating material, a plasticizer, an anti-sticking agent and a solvent. Through the synergistic effect of the compound stabilizer and process control, the stability and dissolution performance of the enteric-coated tablet are synergistically improved, meanwhile, the production process is simplified, and the preparation method is suitable for industrial application.

This invention is applied in the field of medicine, namely in endocrinology, and can be used in the treatment of type 1 diabetes. The invention proposes a combination containing a dipeptidyl peptidase 4 (DPP-4) inhibitor, a proton pump inhibitor (PP1), and γ-aminobutyric acid or γ-aminobutyric acid receptor agonist. This unique combination and dosage of drugs leads to the regeneration (recovery) of pancreatic β-cells, which occurs with a dramatic reduction in insulin requirements up to a total cessation of insulin in some individuals and is intended for the treatment of type 1 diabetes mellitus.

A pharmaceutical formulation according to some embodiments comprises: an immediate-release part for eluting an active ingredient in a pH-independent manner; and an enteric part for eluting the active ingredient in a pH-dependent manner, wherein the active ingredient may comprise a proton pump inhibitor, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof. Some embodiments of the present invention enable immediate absorption of drugs while maintaining prolonged pharmacological efficacy.

Helicobacter pylori (HP) is a chronic bacterium that infects the gastric mucosa. It is widespread in the general population, with an infection rate between 55% and 70%. HP is closely related to gastric ulcers and gastritis. Western medicine treatment for HP infection is relatively complex, including bismuth substituents and proton pump inhibitors plus two antibiotics. Gastric ulcers and gastritis are common digestive system diseases. Compound 1, "Exterminate the Ghost," is a traditional Chinese medicine composition mainly composed of Coptis chinensis, plus Scutellaria baicalensis and Fraxinus chinensis, which can eradicate HP. Compound 2, "Ulcer Relief," is a traditional Chinese medicine composition mainly composed of Coptis chinensis, plus Rheum palmatum and Bletilla striata, which can cure gastric ulcers. Compound 3, "Gasitis Relief," is a traditional Chinese medicine composition mainly composed of Coptis chinensis, plus Glycyrrhiza uralensis or Taraxacum mongolicum, made into a tea bag, which can cure chronic gastritis.

The present invention relates to a pharmaceutical composition a first comprising: unit comprising acetylsalicylic acid or a pharmaceutically acceptable salt thereof; and a second unit comprising a proton pump inhibitor. The pharmaceutical composition according to the present invention is divided into the first unit and the second unit, thus preventing direct contact between the drugs. Therefore, stability is achieved and the effect on the individual release of the respective drugs is minimized, and thus improved elution is exhibited.

This invention provides a method for preparing a proton pump inhibitor thioether intermediate. The method involves reacting 3,5-dimethyl-4-methoxy-2-pyridinemethanethiol as a raw material with paraformaldehyde to obtain an intermediate, which is then further reacted with 4-methoxy-o-phenylenediamine, followed by post-treatment to obtain omeprazole thioether. This preparation method is novel, simple to operate, produces a high-purity product, and is suitable for industrial production.

An aspect provides a pharmaceutical composite formulation containing: a first layer comprising a proton pump inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient, a disintegrant, and a binder; and a second layer comprising, as an active ingredient, an antacid selected from magnesium hydroxide, magnesium oxide, or a mixture thereof.

To provide a pediatric suspension formulation.SOLUTION: The present disclosure relates to storage-stable proton pump inhibitor (PPI) systems comprising a therapeutically effective amount of a PPI or a pharmaceutically acceptable salt thereof, such as omeprazole or a pharmaceutically acceptable salt thereof, which are constituted with water prior to administration. The present disclosure also relates to oral pharmaceutical suspensions comprising water, a therapeutically effective amount of a PPI or a pharmaceutically acceptable salt thereof, such as omeprazole or a pharmaceutically acceptable salt thereof, and one or more buffering agents.SELECTED DRAWING: None

The utility model discloses a proton pump inhibitor quantitative sampling instrument, which comprises an instrument main body and a sealing plate fixedly installed at the upper end of the instrument main body, a fixed cylinder is fixedly installed inside the sealing plate, the inside of the fixed cylinder is in threaded connection with a limiting cylinder, and rotating rods are fixedly installed on the outer side of the upper end of the limiting cylinder at equal angles. And a driving rod is mounted in the limiting cylinder in a sliding manner. According to the quantitative sampling instrument for the proton pump inhibitor, the movement speed of the sealing rubber block can be slowed down through the exhaust hole, bubbles appearing in the sampling instrument are reduced, the sampling accuracy of the sampling instrument is improved, discharging of the sampling instrument can be accelerated through opening and closing of the vent hole, the discharging time is shortened, and the using convenience of the sampling instrument is improved; the fixing cylinder is in threaded connection with the limiting cylinder, the position of the limiting cylinder can be changed through rotation of the limiting cylinder and matching with scale marks, meanwhile, the movement position of the driving rod can be limited, and the using precision of the sampling instrument is improved.

The present application relates to a kind of amoxicillin gastric retention sustained-release preparation, which contains amoxicillin, sustained-release material, swelling agent and other pharmaceutical adjuvant, preferably also contains stabilizer or ion regulator.The combination of the above-mentioned adjuvant can be retained in the stomach for up to 24 hours, the complete release time is 10-24h, which can significantly prolong the retention time of amoxicillin in the stomach, has the advantages of fast floating, high effective concentration of drug in the stomach, long stable concentration time, and is beneficial to reduce the frequency of drug administration of patients;Further preferably, it is made into a double-layer tablet containing immediate-release layer, which can quickly reach effective concentration and also can be released slowly and continuously, maintaining effective concentration for a long time;When combined with proton pump inhibitors such as vonolabian, etc., combination kit or compound, only 1-2 times per day is needed, which can further improve the therapeutic effect and patient compliance.

This invention provides a lyophilized powder injection of a proton pump inhibitor and its use therein, the lyophilized powder injection comprising a compound of formula (I) and an excipient. The powder injection provided by this invention is stable in properties, has controllable quality, and its preparation process is highly reproducible, meeting the needs of commercial production. Formula (I).

Compositions comprising (i) a cross-linked polymeric chelator comprising a plurality of cross-linked polyamine polymer backbone chains and one or more chelators covalently coupled thereto, and (ii) an agent selected from an antacid, a histamine H2-receptor antagonist, a proton pump inhibitor, and a combination thereof. Also disclosed are methods of using a composition comprising the cross-linked polymeric chelator in combination with the agent, e.g., for removing metal from a medium or treating iron overload disease.

The present invention relates to: lipid nanoparticles with improved genetic material delivery efficiency through the regulation of an extracellular matrix and pH control of intracellular organelles; and use thereof. A composition for delivering a genetic material, according to the present invention, comprises lipid nanoparticles and a proton pump inhibitor, whereby the genetic material can be effectively delivered by overcoming various intracellular and extracellular barriers and the limitations of existing delivery systems.

Omeprazole is used as a widely applied proton pump inhibitor and is mainly used for treating various diseases caused by hyperacidity, such as gastric ulcer, duodenal ulcer, reflux esophagitis and the like. The invention relates to a novel application of a commercially available medicine omeprazole, namely the omeprazole has remarkable anti-aging activity. The research on model organism caenorhabditis elegans finds that omeprazole can significantly prolong the life of nematodes. Specifically, when the nematodes are cultured in culture media containing 1.6 mg / mL omeprazole and 3.2 mg / mL omeprazole, the service lives of the nematodes are prolonged by 47.80% and 61.51% respectively, and the effect is extremely rare in current drug research.

The invention relates to the technical field of prescription auditing, and discloses an intelligent pharmacy platform based on linkage of a hospital information system and a reasonable medication system, which screens and manages key controlled medicines such as traditional Chinese medicine decoction pieces, proton pump inhibitors, analgesics, enteral and parenteral nutrition preparations and the like through a clinical pharmacist informatization integrated management system. Through an intelligent management platform, precise control and intervention of traditional Chinese medicine decoction pieces and key monitoring drugs such as proton pump inhibitors, analgesics and enteral and parenteral nutrition preparations in medical institutions are realized, and a standardized medication path is established. The method successfully solves the core problems that the traditional Chinese medicine decoction piece auditing rule is single and does not accord with the reality in the prescription auditing process in the prior art, the medicine is emphatically monitored, and the medicine diameter management of proton pump inhibitor enteral and parenteral nutrition, analgesics and enteral and parenteral nutrition preparations is not in place. A comprehensive and practical solution is provided for optimization of a prescription auditing system and formulation of clinical drug paths.

Omeprazole, as a widely used proton pump inhibitor, is mainly used for the treatment of various diseases caused by excessive gastric acid, such as gastric ulcer, duodenal ulcer and reflux esophagitis. The present application relates to a new use of a commercially available drug omeprazole, i.e. it has significant anti-aging activity. The present application found that omeprazole can significantly prolong the life of nematodes through research using model organisms Caenorhabditis elegans. Specifically, when the nematodes are cultured in a medium containing 1.6 mg / mL and 3.2 mg / mL omeprazole, their life is prolonged by 47.80% and 61.51% respectively, which is extremely rare in current drug research.

The application discloses a 3D printing combination tablet for treating helicobacter pylori infection, which comprises three layers from top to bottom, wherein the first layer is a stomach floating delayed release layer, the second layer is a bismuth agent immediate release layer, and the third layer is an enteric layer; the stomach floating delayed release layer comprises a delayed release shell, an antibiotic inner core and an air chamber, the delayed release shell is wrapped outside the antibiotic inner core and the air chamber, and the air chamber is arranged above the antibiotic inner core; the enteric layer comprises an enteric shell and a proton pump inhibitor tablet core, and the enteric shell is wrapped outside the proton pump inhibitor tablet core; and a drug release channel is arranged at the bottom of the stomach floating delayed release layer. The 3D printing combination tablet can realize the immediate release of the bismuth agent, the delayed release of the antibiotic and the pH-dependent release of the proton pump inhibitor in the quadruple drug formula, and solves the problems of complex taking sequence, poor patient compliance and single drug dosage of the drug formula for treating helicobacter pylori infection on the market.

The embodiment of the invention discloses a helicobacter pylori detection primer group based on a targeted high-throughput sequencing technology, a kit and a detection method and application of the helicobacter pylori detection primer group. The primer group in the embodiment of the invention comprises specific primer pairs aiming at mutation sites of Hp species identification genes, subtype identification genes and various drug resistance related genes and human CYP2C19 genotyping sites. Through an innovative primer design strategy, a tNGS detection system constructed by using the primer group can simultaneously complete Hp infection confirmation, pathogenic subtype distinguishing, drug resistance evaluation of six common antibiotics and host proton pump inhibitor metabolic capability (CYP2C19 genotype) analysis in single detection; and a comprehensive and efficient solution is provided for precise diagnosis and individualized medication of Hp infection.

The invention relates to the field related to treatment or prevention of helicobacter pylori infection, in particular to a compound preparation for treating helicobacter pylori, which comprises the following components: Vonoprasone, rifbutin and metronidazole, and in each unit of the preparation, the Vonoprasone content is 20mg, the rifbutin content is 50mg, and the metronidazole content is 400mg. The compound preparation disclosed by the invention has a unique medicine combination mechanism, and the compound preparation innovatively combines the Vonoprasone, the rifobetine and the metronidazole together. Compared with a traditional proton pump inhibitor, the novel potassium ion competitive acid blocker has the advantages that the unique action mechanism of the novel potassium ion competitive acid blocker enables the novel potassium ion competitive acid blocker to have remarkable advantages in the aspect of inhibiting gastric acid secretion, H < + >-K < + >-ATPase in resting and activated states can be inhibited at the same time, the novel potassium ion competitive acid blocker is slightly influenced by CYP2C19 gene polymorphism, the effect is reversible, the novel potassium ion competitive acid blocker takes effect quickly, and acid is inhibited for a long time.

The present invention relates to a composition comprising Mesdopetam alone or in combination with proton pump inhibitor which can be administered either separately i.e. by co-administration or in a fixed dose combination (FDC) in the treatment of gastrointestinal and related disorders. The present invention provides use of mesdopetam in the manufacture of a medicament for the treatment of gastrointestinal disorders in a subject in need thereof wherein the medicament is to be administered to the subject. The present invention also relates to a method of treating gastrointestinal diseases in a subject in need thereof comprising administering to the subject mesdopetam and pharmaceutical composition.

Described are analogs of aztreonam and disulfiram of Formula I, II, and III. These compounds can be used to treat bacterial infections in a subject. Also disclosed is the use of aztreonam and disulfiram for treating H. pylori infections. Combinations of the disclosed analogs and / or aztreonam and disulfiram with additional antibiotics and proton pump inhibitors are also disclosed.

The present invention relates to a pharmaceutical composition comprising: a first unit comprising acetylsalicylic acid or a pharmaceutically acceptable salt thereof; and a second unit comprising a proton pump inhibitor. The pharmaceutical composition according to the present invention is divided into the first unit and the second unit, thus preventing direct contact between the drugs. Therefore, stability is achieved and the effect on the individual release of the respective drugs is minimized, and thus improved elution is exhibited.

A method of treating and / or preventing gastric ulcers, said method comprising administering by injection a therapeutically effective amount of a composition comprising: c) a first agent selected from the group consisting of: a medium chain triglyceride and a long chain triglyceride; and d) a second agent comprising a proton pump inhibitor or pharmaceutically or veterinary acceptable salt, wherein the composition is adapted for sustained release of a therapeutically effective amount of the proton pump inhibitor to a subject in need thereof.

The invention discloses a pharmaceutical composition for protecting gastric mucosa, a gastric floating buoyant raft system of the pharmaceutical composition and a preparation method of the gastric floating buoyant raft system. The mass ratio of the proton pump inhibitor to the traditional Chinese medicine extract is (1: 2)-(1: 4), and the traditional Chinese medicine extract is prepared from gingerol oil and pogostemon cablin essential oil according to the mass ratio of (0.5-3): 1. The pharmaceutical composition is prepared into a gastric floating raft system, and the dosage form is in a solution state under preparation and in-vitro conditions; after being orally taken and entering the stomach, the gel buoyant raft is rapidly subjected to phase transformation in the environment of low-pH gastric juice and expands to form a layer of light gel buoyant raft which is low in density, compact in structure and certain in mechanical strength. The gel raft can stay on the surface of gastric juice for a long time, so that retention and slow release of the medicine in the stomach are realized, and the local action effect is enhanced. Compared with a single chemical medicine, the compound preparation is mild in medicine property, the irritation is obviously reduced, the curative effect is enhanced through the synergistic effect of multiple components, and the adverse reaction is reduced.

Disclosed herein are liquid diluents, formulations, and kits for preparing reconstituted suspensions of a proton pump inhibitor (e.g., omeprazole). The present disclosure also provides formulations for liquid diluents that do not have a tendency for gel formation following exposure to freeze-thaw cycles.

Disclosed herein are liquid diluents, formulations, and kits for preparing reconstituted suspensions of a proton pump inhibitor (e.g., omeprazole). The present disclosure also provides formulations for liquid diluents that do not have a tendency for gel formation following exposure to freeze-thaw cycles.